AbbVie has announced two positive updates for Canadians living with ulcerative colitis (UC). Canada's Drug Agency (CDA-AMC) has recommended SKYRIZI (risankizumab) to be reimbursed with conditions by public drug plans for the treatment of adults with moderately to severely active UC who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor if certain conditions are met. The CDA-AMC's positive recommendation was informed by feedback from 25 Canadian clinicians and two patient organizations, including the GI Society and Crohn's and Colitis Canada, ensuring that the voices of those living with UC were considered.
AbbVie has also successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI®? for UC and a Letter of Intent (LOI) has been signed by both parties. SKYRIZI is also indicated for the treatment of adult patients with moderately to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, the treatment of adult patients with active psoriatic arthritis and it can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).
